Onkológia 5/2018
Acute myeloblastic leukemias – step forward. Even in the treatment?
Certain changes and progress have been made in acute myeloblastic leukemias in the last two to three years. These changes are concerning the classification of the disease, advance was observed in the discovery of the genomic landscape of the disease, in the development of genetic diagnostic assays, also in detecting of minimal residual disease (MRD), which is in close association with testing of many new drugs targeting specific genetic lesions, in current ongoing numerous studies, phase I and II. Mentioned progress in diagnostics and MRD assessment has led the international expert panel European LeukemiaNet (ELN) and MRD Working Party of the ELN, to renewal the recommendations for diagnostics and management of AML and to established recommendations for MRD assessment in AML.
Keywords: leukemia, classification, MRD, treatment












